Pancreatic cancer gene map could lead to smarter treatments

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have a histological or radiological diagnosis of locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients with borderline resectable disease are not eligible. * Patient must have a tumor lesion that is amenable to a core needle biopsy. * Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied. * Patients must be fit enough to safely undergo a tumor biopsy. * Age 18 years or older. * Eastern Cooperative Group (ECOG) performance status of 1 or less. * Life expectancy of greater than 90 days. * Patients must have normal organ and marrow function * Patients must undergo systemic treatment with m-FOLFIRINOX or nab-paclitaxel as a first line standard systemic palliative treatment or combination treatment with m-FOLFIRINOX or nab-paclitaxel with or without other investigational agents within a clinical trial as a first line palliative treatment. * Ability to understand and willing to sign a written informed consent document. Exclusion Criteria: * Patients with one or more contraindications to tumor biopsy. * Patients who have prior systemic treatment (chemotherapy or any other anti-cancer agent) in advanced setting. * Patients who are currently on anti-cancer treatment including chemotherapy. * Patients with known brain metastases. * Patients with advanced PDAC who are going to be treated with gemcitabine monotherapy in advanced setting. * Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.